A Phase II/III randomized study of R-miniCHOP with or without oral azacitidine (CC-486) in participants age 75 years or older with newly diagnosed diffuse large B cell lymphoma Grade IIIb Follicular Lymphoma transformed lymphoma and high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Lymphoma
  • Age: Between 75 - 100 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) Participants must have histologically or cytologically confirmed DLBCL, Ann Arbor Stage IIX (bulky), III or IV. 2) Participants must have a left ventricular ejection (LVEF) fraction = 45% as measured by echocardiogram or radionuclide (MUGA) ventriculography within 56 days prior to registration. 3) Participants must not have received any prior cytotoxic chemotherapy or rituximab for treatment of the newly diagnosed DLBCL.

You may not be eligible for this study if the following are true:

  • 1) Participants 74 and younger. 2) Participants have active infection (systemic fungal, bacterial, or viral infection) that is not controlled (defined as ongoing signs/symptoms related the infection without improvement despite appropriate antibiotics, antiviral therapy, and/or other treatment).


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.